| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccines | 47 | 2024 | 384 | 7.890 |
Why?
|
| Chagas Disease | 49 | 2026 | 319 | 6.260 |
Why?
|
| Antigens, Helminth | 39 | 2025 | 187 | 5.020 |
Why?
|
| Trypanosoma cruzi | 39 | 2026 | 255 | 4.700 |
Why?
|
| Hookworm Infections | 36 | 2026 | 127 | 4.410 |
Why?
|
| Protozoan Vaccines | 23 | 2026 | 101 | 3.840 |
Why?
|
| Viral Vaccines | 14 | 2020 | 317 | 3.560 |
Why?
|
| Necator americanus | 21 | 2026 | 93 | 3.490 |
Why?
|
| Spike Glycoprotein, Coronavirus | 17 | 2025 | 216 | 3.480 |
Why?
|
| Coronavirus Infections | 13 | 2020 | 351 | 3.080 |
Why?
|
| Neglected Diseases | 16 | 2023 | 153 | 3.000 |
Why?
|
| Recombinant Proteins | 36 | 2023 | 1317 | 2.870 |
Why?
|
| Pneumonia, Viral | 10 | 2020 | 363 | 2.790 |
Why?
|
| Pandemics | 16 | 2022 | 1157 | 2.350 |
Why?
|
| Vaccines, Synthetic | 30 | 2025 | 319 | 2.310 |
Why?
|
| Helminth Proteins | 14 | 2025 | 104 | 2.250 |
Why?
|
| Betacoronavirus | 10 | 2020 | 282 | 2.200 |
Why?
|
| Antibodies, Helminth | 24 | 2025 | 131 | 2.160 |
Why?
|
| Adjuvants, Immunologic | 34 | 2026 | 393 | 2.050 |
Why?
|
| Ancylostomatoidea | 14 | 2023 | 60 | 2.040 |
Why?
|
| Animals | 149 | 2026 | 33857 | 1.750 |
Why?
|
| Nitroimidazoles | 10 | 2026 | 49 | 1.610 |
Why?
|
| Parasitic Diseases | 5 | 2020 | 60 | 1.570 |
Why?
|
| Vaccination | 31 | 2025 | 1051 | 1.560 |
Why?
|
| Leishmaniasis Vaccines | 5 | 2020 | 20 | 1.480 |
Why?
|
| Trypanocidal Agents | 6 | 2026 | 33 | 1.480 |
Why?
|
| Ascariasis | 11 | 2026 | 77 | 1.440 |
Why?
|
| Glutathione Transferase | 9 | 2026 | 147 | 1.400 |
Why?
|
| Antigens, Protozoan | 10 | 2026 | 77 | 1.390 |
Why?
|
| Trichuriasis | 5 | 2025 | 31 | 1.330 |
Why?
|
| Schistosomiasis | 7 | 2024 | 52 | 1.300 |
Why?
|
| Protozoan Proteins | 6 | 2026 | 127 | 1.270 |
Why?
|
| Saccharomycetales | 5 | 2021 | 36 | 1.220 |
Why?
|
| Tropical Medicine | 7 | 2023 | 104 | 1.180 |
Why?
|
| Soil | 6 | 2025 | 76 | 1.180 |
Why?
|
| Gene Expression | 13 | 2021 | 1486 | 1.160 |
Why?
|
| Mice, Inbred BALB C | 32 | 2026 | 977 | 1.150 |
Why?
|
| Helminthiasis | 7 | 2025 | 83 | 1.100 |
Why?
|
| Communicable Disease Control | 7 | 2020 | 141 | 1.100 |
Why?
|
| Biomedical Research | 8 | 2020 | 558 | 1.090 |
Why?
|
| Humans | 167 | 2026 | 130436 | 1.070 |
Why?
|
| Leishmaniasis | 5 | 2023 | 41 | 1.060 |
Why?
|
| Saccharomyces cerevisiae | 5 | 2023 | 398 | 1.060 |
Why?
|
| Schistosomiasis mansoni | 5 | 2023 | 24 | 1.020 |
Why?
|
| Ancylostoma | 12 | 2026 | 99 | 0.990 |
Why?
|
| Severe Acute Respiratory Syndrome | 5 | 2020 | 39 | 0.960 |
Why?
|
| Mice | 61 | 2026 | 18229 | 0.960 |
Why?
|
| Antibodies, Viral | 13 | 2025 | 1174 | 0.960 |
Why?
|
| Antibodies, Neutralizing | 14 | 2025 | 526 | 0.950 |
Why?
|
| Chagas Cardiomyopathy | 8 | 2021 | 46 | 0.940 |
Why?
|
| Lyme Disease | 5 | 2025 | 34 | 0.930 |
Why?
|
| Tetraspanins | 3 | 2016 | 30 | 0.910 |
Why?
|
| Ascaris suum | 6 | 2024 | 32 | 0.870 |
Why?
|
| Vaccines, Subunit | 9 | 2024 | 74 | 0.870 |
Why?
|
| Pichia | 14 | 2017 | 56 | 0.860 |
Why?
|
| Phlebotomus | 2 | 2020 | 14 | 0.790 |
Why?
|
| Protein Domains | 8 | 2025 | 252 | 0.780 |
Why?
|
| Antibodies, Protozoan | 12 | 2026 | 102 | 0.770 |
Why?
|
| Borrelia burgdorferi | 4 | 2025 | 18 | 0.770 |
Why?
|
| Necatoriasis | 5 | 2026 | 39 | 0.750 |
Why?
|
| Aspartic Acid Proteases | 2 | 2019 | 9 | 0.730 |
Why?
|
| Immunogenicity, Vaccine | 7 | 2024 | 126 | 0.710 |
Why?
|
| Aluminum Hydroxide | 9 | 2026 | 41 | 0.690 |
Why?
|
| Viral Envelope Proteins | 2 | 2020 | 155 | 0.680 |
Why?
|
| Political Systems | 1 | 2020 | 2 | 0.670 |
Why?
|
| Global Health | 7 | 2021 | 627 | 0.660 |
Why?
|
| Human Rights | 1 | 2020 | 25 | 0.660 |
Why?
|
| Courage | 1 | 2020 | 4 | 0.650 |
Why?
|
| Anemia | 5 | 2021 | 352 | 0.650 |
Why?
|
| Phospholipids | 2 | 2020 | 99 | 0.640 |
Why?
|
| Aspartic Acid Endopeptidases | 3 | 2018 | 30 | 0.640 |
Why?
|
| Developing Countries | 6 | 2020 | 302 | 0.630 |
Why?
|
| Immunoglobulin Fc Fragments | 3 | 2025 | 28 | 0.630 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 4 | 2025 | 22 | 0.620 |
Why?
|
| Cost-Benefit Analysis | 7 | 2024 | 547 | 0.620 |
Why?
|
| Pepsin A | 1 | 2019 | 11 | 0.620 |
Why?
|
| Alum Compounds | 7 | 2022 | 41 | 0.610 |
Why?
|
| Drug Design | 3 | 2020 | 162 | 0.610 |
Why?
|
| Immunization | 7 | 2022 | 267 | 0.610 |
Why?
|
| Computational Biology | 2 | 2022 | 862 | 0.600 |
Why?
|
| Parasites | 4 | 2024 | 33 | 0.600 |
Why?
|
| Licensure | 1 | 2019 | 14 | 0.600 |
Why?
|
| Fluorometry | 2 | 2017 | 27 | 0.600 |
Why?
|
| Health Policy | 3 | 2020 | 225 | 0.580 |
Why?
|
| Immunoglobulin G | 16 | 2026 | 793 | 0.580 |
Why?
|
| Ultraviolet Rays | 1 | 2019 | 191 | 0.580 |
Why?
|
| Poverty | 8 | 2024 | 454 | 0.570 |
Why?
|
| Onchocerciasis | 4 | 2022 | 22 | 0.560 |
Why?
|
| Emigrants and Immigrants | 3 | 2020 | 169 | 0.560 |
Why?
|
| Technology, Pharmaceutical | 4 | 2017 | 19 | 0.550 |
Why?
|
| Leishmania | 3 | 2023 | 34 | 0.550 |
Why?
|
| Onchocerciasis, Ocular | 1 | 2017 | 4 | 0.540 |
Why?
|
| Mass Vaccination | 2 | 2016 | 14 | 0.530 |
Why?
|
| Public Health | 3 | 2020 | 272 | 0.520 |
Why?
|
| Calcium-Binding Proteins | 2 | 2017 | 322 | 0.520 |
Why?
|
| Onchocerca volvulus | 4 | 2019 | 16 | 0.520 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 2017 | 8 | 0.510 |
Why?
|
| Helminths | 4 | 2024 | 52 | 0.500 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2020 | 395 | 0.480 |
Why?
|
| Honduras | 5 | 2025 | 25 | 0.470 |
Why?
|
| Communication | 1 | 2020 | 540 | 0.470 |
Why?
|
| Female | 67 | 2026 | 70351 | 0.460 |
Why?
|
| Salivary Proteins and Peptides | 3 | 2020 | 18 | 0.450 |
Why?
|
| Trichuris | 5 | 2025 | 26 | 0.450 |
Why?
|
| Cytokines | 11 | 2026 | 1344 | 0.440 |
Why?
|
| Parasite Load | 7 | 2018 | 31 | 0.430 |
Why?
|
| Latin America | 8 | 2020 | 108 | 0.430 |
Why?
|
| Health Personnel | 1 | 2019 | 547 | 0.430 |
Why?
|
| Cost of Illness | 6 | 2025 | 293 | 0.420 |
Why?
|
| Americas | 5 | 2020 | 52 | 0.420 |
Why?
|
| Clinical Trials as Topic | 7 | 2020 | 1121 | 0.420 |
Why?
|
| Disease Eradication | 2 | 2020 | 39 | 0.410 |
Why?
|
| Private Sector | 1 | 2014 | 26 | 0.410 |
Why?
|
| Histamine Release | 1 | 2012 | 10 | 0.380 |
Why?
|
| Schistosoma mansoni | 5 | 2023 | 24 | 0.380 |
Why?
|
| Basophils | 1 | 2012 | 11 | 0.370 |
Why?
|
| Immunoglobulin E | 2 | 2018 | 215 | 0.370 |
Why?
|
| Leishmaniasis, Cutaneous | 4 | 2020 | 50 | 0.370 |
Why?
|
| Ixodes | 2 | 2022 | 20 | 0.370 |
Why?
|
| Immunotherapy | 4 | 2026 | 759 | 0.370 |
Why?
|
| Lyme Disease Vaccines | 4 | 2025 | 11 | 0.370 |
Why?
|
| Larva | 12 | 2025 | 244 | 0.360 |
Why?
|
| Antibody Formation | 6 | 2025 | 227 | 0.360 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2022 | 464 | 0.350 |
Why?
|
| Dogs | 11 | 2022 | 617 | 0.350 |
Why?
|
| Dengue | 1 | 2013 | 124 | 0.350 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2025 | 692 | 0.350 |
Why?
|
| Occupational Medicine | 1 | 2011 | 1 | 0.340 |
Why?
|
| Prevalence | 10 | 2025 | 2683 | 0.340 |
Why?
|
| Labor Unions | 1 | 2011 | 2 | 0.340 |
Why?
|
| Accidents, Occupational | 1 | 2011 | 9 | 0.340 |
Why?
|
| Emigration and Immigration | 2 | 2011 | 80 | 0.340 |
Why?
|
| Work | 1 | 2011 | 12 | 0.340 |
Why?
|
| Lung | 8 | 2025 | 1534 | 0.330 |
Why?
|
| Ancylostomiasis | 7 | 2015 | 62 | 0.320 |
Why?
|
| Delivery of Health Care | 2 | 2019 | 683 | 0.320 |
Why?
|
| Insect Proteins | 2 | 2020 | 96 | 0.310 |
Why?
|
| Intestinal Diseases, Parasitic | 3 | 2020 | 43 | 0.310 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 2025 | 409 | 0.310 |
Why?
|
| Computer Simulation | 5 | 2025 | 671 | 0.300 |
Why?
|
| Vaccines, DNA | 2 | 2022 | 44 | 0.300 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2021 | 126 | 0.300 |
Why?
|
| Cloning, Molecular | 7 | 2021 | 780 | 0.300 |
Why?
|
| Lung Diseases | 2 | 2024 | 397 | 0.290 |
Why?
|
| Zika Virus Infection | 2 | 2022 | 174 | 0.290 |
Why?
|
| Research | 2 | 2020 | 264 | 0.290 |
Why?
|
| Protein Stability | 4 | 2020 | 165 | 0.290 |
Why?
|
| Internationality | 1 | 2009 | 128 | 0.280 |
Why?
|
| Health Services Accessibility | 4 | 2020 | 694 | 0.280 |
Why?
|
| Immunity, Cellular | 6 | 2022 | 194 | 0.280 |
Why?
|
| Antigenic Variation | 2 | 2021 | 37 | 0.270 |
Why?
|
| Markov Chains | 3 | 2024 | 101 | 0.270 |
Why?
|
| Organizations, Nonprofit | 2 | 2015 | 27 | 0.270 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2025 | 785 | 0.260 |
Why?
|
| Amino Acid Sequence | 10 | 2021 | 2397 | 0.260 |
Why?
|
| Cyclins | 3 | 2007 | 93 | 0.260 |
Why?
|
| Protein Conformation | 4 | 2019 | 732 | 0.260 |
Why?
|
| Complement Factor H | 3 | 2025 | 24 | 0.260 |
Why?
|
| Filariasis | 2 | 2018 | 28 | 0.260 |
Why?
|
| Disease Outbreaks | 1 | 2009 | 314 | 0.260 |
Why?
|
| Disease Models, Animal | 16 | 2025 | 4667 | 0.260 |
Why?
|
| Immunoglobulin A | 2 | 2025 | 205 | 0.260 |
Why?
|
| Feces | 5 | 2025 | 720 | 0.260 |
Why?
|
| Brugia malayi | 2 | 2018 | 40 | 0.260 |
Why?
|
| Bacterial Proteins | 2 | 2025 | 944 | 0.260 |
Why?
|
| Young Adult | 13 | 2026 | 9993 | 0.250 |
Why?
|
| Biotechnology | 3 | 2015 | 59 | 0.250 |
Why?
|
| Macaca mulatta | 4 | 2021 | 492 | 0.250 |
Why?
|
| Psychodidae | 2 | 2017 | 14 | 0.250 |
Why?
|
| Temperature | 3 | 2017 | 289 | 0.250 |
Why?
|
| Superantigens | 2 | 2017 | 20 | 0.250 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2024 | 122 | 0.250 |
Why?
|
| Microbiota | 2 | 2023 | 438 | 0.250 |
Why?
|
| Cultural Diversity | 2 | 2021 | 81 | 0.250 |
Why?
|
| N-Glycosyl Hydrolases | 2 | 2016 | 13 | 0.250 |
Why?
|
| Stomach | 2 | 2026 | 270 | 0.250 |
Why?
|
| Anthelmintics | 5 | 2016 | 55 | 0.240 |
Why?
|
| Rural Population | 2 | 2020 | 272 | 0.240 |
Why?
|
| Leishmania donovani | 2 | 2016 | 26 | 0.240 |
Why?
|
| Swine Diseases | 2 | 2024 | 40 | 0.240 |
Why?
|
| Budgets | 1 | 2006 | 15 | 0.240 |
Why?
|
| Single-Chain Antibodies | 1 | 2026 | 42 | 0.240 |
Why?
|
| Lipid A | 4 | 2019 | 23 | 0.240 |
Why?
|
| Technology | 2 | 2024 | 68 | 0.240 |
Why?
|
| Adaptive Immunity | 2 | 2024 | 102 | 0.230 |
Why?
|
| Immunity, Innate | 3 | 2024 | 410 | 0.230 |
Why?
|
| Stomach Diseases | 1 | 2026 | 56 | 0.230 |
Why?
|
| Transduction, Genetic | 2 | 2024 | 277 | 0.230 |
Why?
|
| Retinoblastoma Protein | 2 | 2005 | 78 | 0.230 |
Why?
|
| Proteome | 2 | 2025 | 286 | 0.230 |
Why?
|
| Th2 Cells | 5 | 2021 | 188 | 0.220 |
Why?
|
| Toxocariasis | 2 | 2015 | 29 | 0.220 |
Why?
|
| Vaccination Coverage | 2 | 2022 | 40 | 0.220 |
Why?
|
| Mitogens | 2 | 2001 | 30 | 0.220 |
Why?
|
| Toll-Like Receptor 4 | 3 | 2022 | 141 | 0.220 |
Why?
|
| Schistosoma | 1 | 2024 | 13 | 0.210 |
Why?
|
| Health Care Costs | 3 | 2025 | 406 | 0.210 |
Why?
|
| Blood Donors | 2 | 2014 | 58 | 0.210 |
Why?
|
| Chitinases | 1 | 2024 | 4 | 0.210 |
Why?
|
| Neutralization Tests | 2 | 2024 | 226 | 0.210 |
Why?
|
| Human T-lymphotropic virus 1 | 4 | 2005 | 63 | 0.210 |
Why?
|
| HIV-1 | 2 | 2024 | 492 | 0.210 |
Why?
|
| Antigens, Viral | 2 | 2018 | 391 | 0.200 |
Why?
|
| Immunity | 3 | 2020 | 179 | 0.200 |
Why?
|
| Cyclin D1 | 4 | 2007 | 106 | 0.200 |
Why?
|
| T-Lymphocytes | 4 | 2021 | 1712 | 0.200 |
Why?
|
| Monocytes | 3 | 2020 | 336 | 0.200 |
Why?
|
| Male | 31 | 2026 | 64471 | 0.200 |
Why?
|
| Leishmania mexicana | 1 | 2023 | 6 | 0.200 |
Why?
|
| Hypersensitivity | 2 | 2018 | 227 | 0.190 |
Why?
|
| Adult | 19 | 2026 | 31120 | 0.190 |
Why?
|
| Coinfection | 2 | 2026 | 185 | 0.190 |
Why?
|
| Technology Transfer | 2 | 2020 | 8 | 0.190 |
Why?
|
| Borrelia burgdorferi Group | 1 | 2022 | 4 | 0.190 |
Why?
|
| Growth Substances | 2 | 1999 | 99 | 0.190 |
Why?
|
| Gabon | 4 | 2024 | 8 | 0.190 |
Why?
|
| Immunoglobulin M | 3 | 2018 | 212 | 0.180 |
Why?
|
| Endemic Diseases | 2 | 2012 | 60 | 0.180 |
Why?
|
| Drug Stability | 3 | 2017 | 56 | 0.180 |
Why?
|
| Models, Animal | 1 | 2024 | 451 | 0.180 |
Why?
|
| Sensitivity and Specificity | 2 | 2025 | 2088 | 0.180 |
Why?
|
| G1 Phase | 3 | 2007 | 68 | 0.180 |
Why?
|
| Adolescent | 14 | 2026 | 20725 | 0.180 |
Why?
|
| Cytochalasin D | 1 | 2001 | 10 | 0.180 |
Why?
|
| Cyclin A | 1 | 2001 | 17 | 0.180 |
Why?
|
| Microbiology | 1 | 2021 | 7 | 0.180 |
Why?
|
| Glucosides | 2 | 2019 | 54 | 0.180 |
Why?
|
| United States | 11 | 2026 | 11874 | 0.180 |
Why?
|
| Schistosomiasis haematobia | 1 | 2021 | 11 | 0.180 |
Why?
|
| Middle Aged | 16 | 2026 | 28395 | 0.180 |
Why?
|
| RNA, Protozoan | 1 | 2021 | 10 | 0.180 |
Why?
|
| Intestinal Volvulus | 1 | 2022 | 41 | 0.180 |
Why?
|
| Heart | 6 | 2023 | 659 | 0.180 |
Why?
|
| Biomarkers | 4 | 2025 | 3385 | 0.170 |
Why?
|
| Host-Parasite Interactions | 2 | 2020 | 71 | 0.170 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 144 | 0.170 |
Why?
|
| Vibrio cholerae | 1 | 2021 | 33 | 0.170 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2021 | 32 | 0.170 |
Why?
|
| Zebrafish | 1 | 2024 | 417 | 0.170 |
Why?
|
| Brazil | 5 | 2024 | 116 | 0.170 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2001 | 98 | 0.170 |
Why?
|
| Variant Surface Glycoproteins, Trypanosoma | 2 | 2018 | 6 | 0.170 |
Why?
|
| Cysteine Endopeptidases | 3 | 2024 | 110 | 0.170 |
Why?
|
| Cholera | 1 | 2021 | 39 | 0.170 |
Why?
|
| Bacterial Vaccines | 1 | 2021 | 101 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 8 | 2025 | 4715 | 0.170 |
Why?
|
| Protein Structure, Tertiary | 2 | 2021 | 715 | 0.170 |
Why?
|
| Vaccines, Inactivated | 1 | 2021 | 149 | 0.170 |
Why?
|
| Malaria, Falciparum | 1 | 2021 | 58 | 0.170 |
Why?
|
| Borrelia | 1 | 2022 | 84 | 0.170 |
Why?
|
| Plasmodium falciparum | 1 | 2021 | 81 | 0.170 |
Why?
|
| Th1 Cells | 5 | 2022 | 159 | 0.160 |
Why?
|
| Schistosoma haematobium | 2 | 2021 | 17 | 0.160 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2020 | 13 | 0.160 |
Why?
|
| Cytoskeleton | 1 | 2001 | 167 | 0.160 |
Why?
|
| Cross Protection | 1 | 2020 | 10 | 0.160 |
Why?
|
| Health Communication | 1 | 2020 | 30 | 0.160 |
Why?
|
| Blastocystis Infections | 1 | 2020 | 5 | 0.160 |
Why?
|
| Blastocystis | 1 | 2020 | 6 | 0.160 |
Why?
|
| Models, Economic | 2 | 2021 | 59 | 0.160 |
Why?
|
| Antibodies | 3 | 2022 | 320 | 0.160 |
Why?
|
| Monkey Diseases | 1 | 2020 | 17 | 0.160 |
Why?
|
| Interleukin-17 | 1 | 2021 | 125 | 0.160 |
Why?
|
| Zika Virus | 1 | 2022 | 151 | 0.160 |
Why?
|
| Politics | 1 | 2020 | 59 | 0.160 |
Why?
|
| Down-Regulation | 3 | 2007 | 649 | 0.160 |
Why?
|
| Ticks | 1 | 2020 | 34 | 0.160 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2020 | 137 | 0.160 |
Why?
|
| Circular Dichroism | 3 | 2018 | 62 | 0.150 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2019 | 21 | 0.150 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2019 | 40 | 0.150 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 1999 | 20 | 0.150 |
Why?
|
| Biological Products | 1 | 2022 | 143 | 0.150 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2019 | 40 | 0.150 |
Why?
|
| Lymphokines | 1 | 2019 | 61 | 0.150 |
Why?
|
| Morals | 1 | 2020 | 73 | 0.150 |
Why?
|
| Cysteine | 2 | 2017 | 137 | 0.150 |
Why?
|
| Protein Subunits | 1 | 2020 | 158 | 0.150 |
Why?
|
| Antigens, Bacterial | 2 | 2025 | 318 | 0.150 |
Why?
|
| Actins | 1 | 2001 | 315 | 0.150 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2020 | 153 | 0.150 |
Why?
|
| STAT3 Transcription Factor | 1 | 2021 | 228 | 0.150 |
Why?
|
| Eosinophils | 1 | 2020 | 120 | 0.150 |
Why?
|
| Ascaris | 3 | 2026 | 14 | 0.150 |
Why?
|
| Th17 Cells | 1 | 2020 | 97 | 0.150 |
Why?
|
| Promoter Regions, Genetic | 2 | 2007 | 1210 | 0.150 |
Why?
|
| B-Lymphocytes | 5 | 2025 | 511 | 0.150 |
Why?
|
| Sanitation | 2 | 2017 | 16 | 0.150 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 105 | 0.150 |
Why?
|
| Extracellular Matrix | 2 | 1999 | 232 | 0.150 |
Why?
|
| Candidemia | 1 | 2019 | 43 | 0.150 |
Why?
|
| Life Cycle Stages | 4 | 2025 | 25 | 0.140 |
Why?
|
| Retinol-Binding Proteins | 1 | 2018 | 21 | 0.140 |
Why?
|
| Internet | 1 | 2022 | 422 | 0.140 |
Why?
|
| Antibodies, Catalytic | 1 | 2018 | 7 | 0.140 |
Why?
|
| Cricetinae | 4 | 2012 | 361 | 0.140 |
Why?
|
| Protein Folding | 1 | 2019 | 215 | 0.140 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2018 | 353 | 0.140 |
Why?
|
| Epitopes | 4 | 2024 | 323 | 0.140 |
Why?
|
| Mutant Proteins | 2 | 2016 | 112 | 0.140 |
Why?
|
| International Cooperation | 2 | 2022 | 160 | 0.140 |
Why?
|
| Protective Agents | 1 | 2018 | 34 | 0.140 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2018 | 37 | 0.140 |
Why?
|
| Administration, Intranasal | 3 | 2024 | 130 | 0.140 |
Why?
|
| Nippostrongylus | 1 | 2018 | 3 | 0.140 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 148 | 0.140 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2018 | 56 | 0.140 |
Why?
|
| Strongylida Infections | 1 | 2018 | 14 | 0.140 |
Why?
|
| Plants, Genetically Modified | 2 | 2015 | 39 | 0.140 |
Why?
|
| Milk Proteins | 1 | 2018 | 95 | 0.140 |
Why?
|
| Premature Birth | 1 | 2022 | 419 | 0.140 |
Why?
|
| HLA-A Antigens | 1 | 2018 | 33 | 0.140 |
Why?
|
| HLA-B Antigens | 1 | 2018 | 30 | 0.140 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2018 | 56 | 0.140 |
Why?
|
| Freezing | 1 | 2017 | 27 | 0.140 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 525 | 0.140 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 351 | 0.130 |
Why?
|
| Myocardium | 2 | 2019 | 857 | 0.130 |
Why?
|
| Interferon-gamma | 5 | 2019 | 550 | 0.130 |
Why?
|
| Antiparasitic Agents | 1 | 2017 | 28 | 0.130 |
Why?
|
| Membrane Proteins | 2 | 2024 | 1592 | 0.130 |
Why?
|
| Parasitemia | 4 | 2019 | 25 | 0.130 |
Why?
|
| Gene Products, tax | 4 | 2005 | 46 | 0.130 |
Why?
|
| Erythrocytes | 1 | 2018 | 187 | 0.130 |
Why?
|
| Acute Disease | 2 | 2018 | 1150 | 0.130 |
Why?
|
| Drug Discovery | 2 | 2015 | 179 | 0.130 |
Why?
|
| Genetic Engineering | 1 | 2018 | 161 | 0.130 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2021 | 966 | 0.130 |
Why?
|
| Up-Regulation | 1 | 1999 | 827 | 0.130 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2018 | 196 | 0.130 |
Why?
|
| Fluorescence | 1 | 2017 | 94 | 0.130 |
Why?
|
| Drug Resistance | 1 | 2017 | 243 | 0.130 |
Why?
|
| Software | 1 | 2022 | 731 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 452 | 0.130 |
Why?
|
| Toll-Like Receptors | 1 | 2017 | 83 | 0.120 |
Why?
|
| Genetic Vectors | 4 | 2024 | 897 | 0.120 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 612 | 0.120 |
Why?
|
| Cell Line | 7 | 2021 | 2557 | 0.120 |
Why?
|
| Skin | 2 | 2012 | 536 | 0.120 |
Why?
|
| Housing | 2 | 2020 | 74 | 0.120 |
Why?
|
| Helicobacter Infections | 1 | 2026 | 1307 | 0.120 |
Why?
|
| Chromatography, Gel | 2 | 2016 | 64 | 0.120 |
Why?
|
| Fatty Acid Transport Proteins | 1 | 2016 | 11 | 0.120 |
Why?
|
| Immunologic Memory | 1 | 2018 | 197 | 0.120 |
Why?
|
| Staining and Labeling | 1 | 2017 | 166 | 0.120 |
Why?
|
| Tropical Climate | 2 | 2014 | 51 | 0.120 |
Why?
|
| Biophysical Phenomena | 2 | 2013 | 39 | 0.120 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2017 | 150 | 0.120 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2016 | 22 | 0.120 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 1595 | 0.120 |
Why?
|
| Toxocara canis | 1 | 2015 | 8 | 0.120 |
Why?
|
| Antiprotozoal Agents | 1 | 2016 | 41 | 0.120 |
Why?
|
| Primates | 1 | 2016 | 81 | 0.120 |
Why?
|
| Fluorescent Dyes | 1 | 2017 | 245 | 0.120 |
Why?
|
| Immunodominant Epitopes | 1 | 2015 | 46 | 0.120 |
Why?
|
| Child | 11 | 2025 | 26094 | 0.120 |
Why?
|
| Seroepidemiologic Studies | 3 | 2024 | 167 | 0.110 |
Why?
|
| Nuclear Proteins | 1 | 2001 | 1218 | 0.110 |
Why?
|
| Metalloendopeptidases | 2 | 2006 | 101 | 0.110 |
Why?
|
| Child, Preschool | 6 | 2025 | 14943 | 0.110 |
Why?
|
| Universities | 1 | 2015 | 127 | 0.110 |
Why?
|
| Fibrosis | 3 | 2022 | 418 | 0.110 |
Why?
|
| Escherichia coli | 4 | 2024 | 991 | 0.110 |
Why?
|
| Central America | 1 | 2014 | 21 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2896 | 0.110 |
Why?
|
| Double-Blind Method | 3 | 2026 | 1621 | 0.110 |
Why?
|
| Fund Raising | 1 | 2014 | 6 | 0.100 |
Why?
|
| Molecular Sequence Data | 9 | 2011 | 3469 | 0.100 |
Why?
|
| Cardiomyopathies | 1 | 2019 | 518 | 0.100 |
Why?
|
| Caribbean Region | 1 | 2014 | 19 | 0.100 |
Why?
|
| Viral Load | 3 | 2021 | 407 | 0.100 |
Why?
|
| Poverty Areas | 1 | 2014 | 36 | 0.100 |
Why?
|
| Single-Blind Method | 2 | 2024 | 235 | 0.100 |
Why?
|
| Immunoglobulins | 2 | 2012 | 156 | 0.100 |
Why?
|
| Excipients | 1 | 2013 | 13 | 0.100 |
Why?
|
| Research Support as Topic | 1 | 2014 | 61 | 0.100 |
Why?
|
| Capacity Building | 1 | 2013 | 26 | 0.100 |
Why?
|
| Immunity, Mucosal | 2 | 2025 | 97 | 0.100 |
Why?
|
| Education, Graduate | 1 | 2013 | 21 | 0.100 |
Why?
|
| Drug Compounding | 1 | 2013 | 39 | 0.100 |
Why?
|
| Survival Analysis | 4 | 2018 | 1483 | 0.100 |
Why?
|
| Registries | 1 | 2020 | 1607 | 0.100 |
Why?
|
| Intestinal Diseases | 1 | 2014 | 67 | 0.100 |
Why?
|
| Gene Expression Regulation | 5 | 2020 | 2333 | 0.100 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1993 | 3 | 0.100 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 1993 | 10 | 0.100 |
Why?
|
| Influenza Vaccines | 1 | 2018 | 501 | 0.100 |
Why?
|
| Chronic Disease | 5 | 2021 | 1239 | 0.100 |
Why?
|
| Vaccines, Combined | 2 | 2023 | 40 | 0.100 |
Why?
|
| Cuba | 2 | 2022 | 7 | 0.100 |
Why?
|
| Texas | 5 | 2024 | 3642 | 0.090 |
Why?
|
| Immunotherapy, Active | 1 | 2012 | 18 | 0.090 |
Why?
|
| Program Development | 1 | 2013 | 182 | 0.090 |
Why?
|
| Mexico | 3 | 2020 | 190 | 0.090 |
Why?
|
| Socioeconomic Factors | 4 | 2020 | 901 | 0.090 |
Why?
|
| Oncogenes | 1 | 1993 | 163 | 0.090 |
Why?
|
| CD13 Antigens | 1 | 2012 | 10 | 0.090 |
Why?
|
| Cricetulus | 2 | 2025 | 89 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2004 | 82 | 0.090 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2020 | 126 | 0.090 |
Why?
|
| CHO Cells | 2 | 2025 | 151 | 0.090 |
Why?
|
| Malaria Vaccines | 1 | 2012 | 23 | 0.090 |
Why?
|
| Plasmodium vivax | 1 | 2012 | 21 | 0.090 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 254 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 3029 | 0.090 |
Why?
|
| Immunization, Passive | 1 | 2022 | 122 | 0.090 |
Why?
|
| Research Personnel | 1 | 2013 | 141 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2004 | 589 | 0.090 |
Why?
|
| Alabama | 2 | 2024 | 44 | 0.090 |
Why?
|
| Esophagus | 2 | 2011 | 232 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2012 | 319 | 0.080 |
Why?
|
| Injections, Intramuscular | 2 | 2024 | 185 | 0.080 |
Why?
|
| Italy | 1 | 2011 | 114 | 0.080 |
Why?
|
| Insect Vectors | 1 | 2012 | 113 | 0.080 |
Why?
|
| Patient Rights | 1 | 2011 | 49 | 0.080 |
Why?
|
| Aging | 1 | 2018 | 1243 | 0.080 |
Why?
|
| Binding Sites | 3 | 2022 | 1136 | 0.080 |
Why?
|
| Flow Cytometry | 3 | 2023 | 766 | 0.080 |
Why?
|
| Risk Factors | 5 | 2020 | 10948 | 0.080 |
Why?
|
| Mice, Inbred AKR | 2 | 2022 | 15 | 0.080 |
Why?
|
| Membrane Glycoproteins | 1 | 2012 | 409 | 0.080 |
Why?
|
| Disease Progression | 3 | 2023 | 2194 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2001 | 106 | 0.080 |
Why?
|
| Factor Xa Inhibitors | 1 | 2011 | 59 | 0.080 |
Why?
|
| Insurance, Health | 1 | 2011 | 141 | 0.080 |
Why?
|
| Sequence Alignment | 4 | 2017 | 583 | 0.080 |
Why?
|
| Pregnancy | 5 | 2022 | 7394 | 0.080 |
Why?
|
| Cell Cycle | 6 | 2007 | 596 | 0.080 |
Why?
|
| Insurance Coverage | 1 | 2011 | 117 | 0.080 |
Why?
|
| Hepatitis B Vaccines | 2 | 2022 | 49 | 0.080 |
Why?
|
| Heme | 1 | 2010 | 46 | 0.080 |
Why?
|
| Chlamydia trachomatis | 1 | 2009 | 28 | 0.080 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2018 | 360 | 0.080 |
Why?
|
| Porins | 1 | 2009 | 37 | 0.080 |
Why?
|
| World Health Organization | 3 | 2016 | 116 | 0.070 |
Why?
|
| Fermentation | 2 | 2020 | 66 | 0.070 |
Why?
|
| Health Status | 1 | 2011 | 371 | 0.070 |
Why?
|
| Crystallography, X-Ray | 2 | 2025 | 364 | 0.070 |
Why?
|
| Mass Screening | 1 | 2014 | 810 | 0.070 |
Why?
|
| Protein Binding | 3 | 2021 | 1656 | 0.070 |
Why?
|
| Molecular Weight | 2 | 2020 | 277 | 0.070 |
Why?
|
| Transcriptional Activation | 3 | 2014 | 418 | 0.070 |
Why?
|
| Metabolome | 2 | 2021 | 325 | 0.070 |
Why?
|
| Interleukin-5 | 2 | 2018 | 50 | 0.070 |
Why?
|
| Swine | 2 | 2024 | 1184 | 0.070 |
Why?
|
| Healthy Volunteers | 2 | 2019 | 154 | 0.070 |
Why?
|
| Lymphocyte Activation | 2 | 2007 | 633 | 0.070 |
Why?
|
| Viral Regulatory and Accessory Proteins | 2 | 2004 | 32 | 0.070 |
Why?
|
| Cell Adhesion | 3 | 1999 | 309 | 0.070 |
Why?
|
| Models, Molecular | 2 | 2025 | 1061 | 0.070 |
Why?
|
| Interleukin-4 | 2 | 2018 | 145 | 0.070 |
Why?
|
| Viral Proteins | 2 | 2014 | 338 | 0.070 |
Why?
|
| 3T3 Cells | 3 | 2004 | 119 | 0.070 |
Why?
|
| Fibroblasts | 3 | 2019 | 852 | 0.070 |
Why?
|
| Gerbillinae | 2 | 2018 | 53 | 0.070 |
Why?
|
| Peptides | 1 | 2011 | 704 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2025 | 978 | 0.070 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2004 | 125 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2024 | 2551 | 0.060 |
Why?
|
| Aged | 9 | 2022 | 20888 | 0.060 |
Why?
|
| Dog Diseases | 2 | 2005 | 59 | 0.060 |
Why?
|
| Treatment Outcome | 6 | 2020 | 12834 | 0.060 |
Why?
|
| BRCA1 Protein | 1 | 2007 | 79 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 679 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2011 | 601 | 0.060 |
Why?
|
| Connective Tissue | 1 | 2006 | 26 | 0.060 |
Why?
|
| Animals, Genetically Modified | 1 | 2026 | 327 | 0.060 |
Why?
|
| Transgenes | 1 | 2026 | 322 | 0.060 |
Why?
|
| Antinematodal Agents | 1 | 2005 | 11 | 0.060 |
Why?
|
| Freeze Drying | 1 | 2024 | 13 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2014 | 3675 | 0.060 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2020 | 92 | 0.050 |
Why?
|
| South Carolina | 1 | 2024 | 10 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 1082 | 0.050 |
Why?
|
| Virus Replication | 2 | 2004 | 607 | 0.050 |
Why?
|
| Mississippi | 1 | 2024 | 35 | 0.050 |
Why?
|
| Phosphorylation | 3 | 2007 | 1571 | 0.050 |
Why?
|
| Louisiana | 1 | 2024 | 137 | 0.050 |
Why?
|
| Protein Structure, Secondary | 2 | 2018 | 235 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 1287 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2024 | 110 | 0.050 |
Why?
|
| Hepatomegaly | 1 | 2023 | 22 | 0.050 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2014 | 51 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2005 | 238 | 0.050 |
Why?
|
| Phylogeny | 2 | 2020 | 687 | 0.050 |
Why?
|
| PPAR alpha | 1 | 2023 | 54 | 0.050 |
Why?
|
| Protein Transport | 1 | 2025 | 367 | 0.050 |
Why?
|
| Infection Control | 1 | 2005 | 162 | 0.050 |
Why?
|
| Transcription, Genetic | 3 | 2004 | 1367 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2024 | 364 | 0.050 |
Why?
|
| Culture Media | 1 | 2014 | 169 | 0.050 |
Why?
|
| North America | 2 | 2014 | 256 | 0.050 |
Why?
|
| Public-Private Sector Partnerships | 2 | 2013 | 17 | 0.050 |
Why?
|
| Benzoin | 1 | 2023 | 6 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2025 | 358 | 0.050 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2024 | 116 | 0.050 |
Why?
|
| Environment | 1 | 2024 | 149 | 0.050 |
Why?
|
| Cooperative Behavior | 2 | 2015 | 222 | 0.050 |
Why?
|
| Malaria | 2 | 2015 | 95 | 0.050 |
Why?
|
| Intestines | 3 | 2017 | 587 | 0.050 |
Why?
|
| Antigens | 1 | 2023 | 104 | 0.050 |
Why?
|
| Perforin | 1 | 2022 | 24 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2025 | 417 | 0.050 |
Why?
|
| Mammals | 1 | 2024 | 251 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2014 | 233 | 0.050 |
Why?
|
| Cell Differentiation | 3 | 2023 | 1920 | 0.050 |
Why?
|
| China | 2 | 2019 | 278 | 0.050 |
Why?
|
| Onchocerca | 1 | 2022 | 6 | 0.050 |
Why?
|
| DNA, Complementary | 2 | 2015 | 425 | 0.050 |
Why?
|
| Parasite Egg Count | 3 | 2007 | 28 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2021 | 500 | 0.050 |
Why?
|
| Cell Proliferation | 4 | 2018 | 2464 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 6788 | 0.050 |
Why?
|
| Ivermectin | 1 | 2022 | 8 | 0.050 |
Why?
|
| Retinoblastoma-Like Protein p107 | 1 | 2001 | 3 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2024 | 510 | 0.040 |
Why?
|
| Infant, Low Birth Weight | 1 | 2022 | 168 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2024 | 805 | 0.040 |
Why?
|
| Morbidity | 1 | 2022 | 257 | 0.040 |
Why?
|
| Time Factors | 3 | 2017 | 6200 | 0.040 |
Why?
|
| Masks | 1 | 2022 | 37 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2022 | 93 | 0.040 |
Why?
|
| Hybridomas | 1 | 2021 | 30 | 0.040 |
Why?
|
| Infant | 4 | 2022 | 13228 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 1999 | 576 | 0.040 |
Why?
|
| Blindness | 1 | 2022 | 70 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 2022 | 93 | 0.040 |
Why?
|
| Echocardiography | 2 | 2019 | 1127 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2021 | 65 | 0.040 |
Why?
|
| Australia | 1 | 2021 | 170 | 0.040 |
Why?
|
| Employment | 1 | 2021 | 71 | 0.040 |
Why?
|
| Synteny | 1 | 2021 | 66 | 0.040 |
Why?
|
| Tropism | 1 | 2020 | 9 | 0.040 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2022 | 136 | 0.040 |
Why?
|
| Cattle | 1 | 2022 | 502 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2021 | 191 | 0.040 |
Why?
|
| RNA | 1 | 2024 | 515 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 2 | 1995 | 599 | 0.040 |
Why?
|
| Unemployment | 1 | 2020 | 23 | 0.040 |
Why?
|
| Proteomics | 1 | 2025 | 616 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2020 | 95 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2018 | 3830 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2020 | 84 | 0.040 |
Why?
|
| Medically Underserved Area | 1 | 2020 | 87 | 0.040 |
Why?
|
| Multigene Family | 1 | 2021 | 289 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 2020 | 59 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2001 | 302 | 0.040 |
Why?
|
| Receptors, Fibronectin | 1 | 1999 | 7 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2020 | 396 | 0.040 |
Why?
|
| Aluminum Compounds | 2 | 2012 | 16 | 0.040 |
Why?
|
| Cyclin E | 1 | 1999 | 30 | 0.040 |
Why?
|
| Endothelin-1 | 1 | 2019 | 40 | 0.040 |
Why?
|
| Food Supply | 1 | 2020 | 91 | 0.040 |
Why?
|
| Editorial Policies | 1 | 2020 | 49 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 1999 | 53 | 0.040 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 1999 | 82 | 0.040 |
Why?
|
| Nifurtimox | 1 | 2019 | 3 | 0.040 |
Why?
|
| Mice, Inbred ICR | 1 | 2019 | 137 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 278 | 0.040 |
Why?
|
| Chemokines | 1 | 2019 | 126 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 173 | 0.040 |
Why?
|
| Ovalbumin | 1 | 2018 | 114 | 0.040 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2020 | 192 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 151 | 0.040 |
Why?
|
| Vitamin A | 1 | 2018 | 57 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2018 | 98 | 0.040 |
Why?
|
| Health Services | 1 | 2018 | 69 | 0.030 |
Why?
|
| Receptors, CCR2 | 1 | 2018 | 23 | 0.030 |
Why?
|
| Receptors, CXCR3 | 1 | 2018 | 23 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2019 | 171 | 0.030 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2018 | 71 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2018 | 71 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2020 | 410 | 0.030 |
Why?
|
| Entamoeba histolytica | 1 | 2017 | 10 | 0.030 |
Why?
|
| Apoptosis | 4 | 2005 | 1828 | 0.030 |
Why?
|
| Cryptosporidium | 1 | 2017 | 27 | 0.030 |
Why?
|
| Strongyloides stercoralis | 1 | 2017 | 24 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2018 | 93 | 0.030 |
Why?
|
| Sequence Analysis | 1 | 2017 | 50 | 0.030 |
Why?
|
| Cholera Toxin | 1 | 2017 | 44 | 0.030 |
Why?
|
| Industrial Microbiology | 1 | 2017 | 8 | 0.030 |
Why?
|
| Proteins | 1 | 2023 | 1008 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2018 | 187 | 0.030 |
Why?
|
| Vaccine Potency | 1 | 2017 | 9 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 585 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2017 | 140 | 0.030 |
Why?
|
| Drug Storage | 1 | 2017 | 18 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2018 | 331 | 0.030 |
Why?
|
| Drug Carriers | 1 | 2017 | 116 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2022 | 8519 | 0.030 |
Why?
|
| Helicobacter pylori | 1 | 2026 | 1367 | 0.030 |
Why?
|
| Serine | 1 | 2017 | 161 | 0.030 |
Why?
|
| Incidence | 2 | 2014 | 3313 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2022 | 801 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2016 | 101 | 0.030 |
Why?
|
| Cyclin D2 | 2 | 2007 | 14 | 0.030 |
Why?
|
| Dynamic Light Scattering | 1 | 2016 | 9 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2018 | 731 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2017 | 423 | 0.030 |
Why?
|
| Neutrophils | 1 | 2018 | 364 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1610 | 0.030 |
Why?
|
| Lectins | 1 | 2015 | 50 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 1995 | 37 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2016 | 325 | 0.030 |
Why?
|
| Drug Industry | 1 | 2015 | 48 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2015 | 164 | 0.030 |
Why?
|
| Asia, Southeastern | 1 | 2015 | 22 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2016 | 149 | 0.030 |
Why?
|
| Muscles | 1 | 1995 | 202 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 1483 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 510 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 115 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2017 | 582 | 0.030 |
Why?
|
| Goals | 1 | 2015 | 126 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2017 | 437 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 1456 | 0.030 |
Why?
|
| Spleen | 1 | 2015 | 258 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 2599 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 262 | 0.030 |
Why?
|
| Myocytes, Cardiac | 1 | 2019 | 670 | 0.030 |
Why?
|
| Topography, Medical | 1 | 2014 | 6 | 0.030 |
Why?
|
| Parasitology | 1 | 2014 | 7 | 0.030 |
Why?
|
| Macrophages | 1 | 2018 | 660 | 0.030 |
Why?
|
| Ascaris lumbricoides | 1 | 2014 | 20 | 0.030 |
Why?
|
| Influenza, Human | 1 | 2020 | 702 | 0.030 |
Why?
|
| Glycosylation | 1 | 2013 | 127 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2013 | 35 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 1016 | 0.020 |
Why?
|
| Oncogene Proteins v-myb | 1 | 1993 | 4 | 0.020 |
Why?
|
| Public Sector | 1 | 2013 | 17 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 1993 | 9 | 0.020 |
Why?
|
| South America | 1 | 2013 | 45 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2013 | 68 | 0.020 |
Why?
|
| Absenteeism | 1 | 2013 | 20 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 1993 | 159 | 0.020 |
Why?
|
| Chick Embryo | 1 | 1993 | 122 | 0.020 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2015 | 238 | 0.020 |
Why?
|
| Viscera | 1 | 2013 | 56 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2013 | 99 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2016 | 299 | 0.020 |
Why?
|
| Base Sequence | 2 | 1995 | 2734 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2005 | 1104 | 0.020 |
Why?
|
| Academies and Institutes | 1 | 2013 | 81 | 0.020 |
Why?
|
| Efficiency | 1 | 2013 | 74 | 0.020 |
Why?
|
| Phosphates | 1 | 2012 | 111 | 0.020 |
Why?
|
| Plasmodium berghei | 1 | 2012 | 13 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 1693 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2012 | 151 | 0.020 |
Why?
|
| Anopheles | 1 | 2012 | 24 | 0.020 |
Why?
|
| Europe | 1 | 2013 | 364 | 0.020 |
Why?
|
| Genotype | 1 | 2018 | 2589 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 1002 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2004 | 4670 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2018 | 1541 | 0.020 |
Why?
|
| Chromatin | 2 | 2004 | 504 | 0.020 |
Why?
|
| Crystallization | 1 | 2010 | 83 | 0.020 |
Why?
|
| Solubility | 1 | 2010 | 117 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2007 | 2894 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2014 | 1444 | 0.020 |
Why?
|
| HIV Infections | 2 | 2015 | 2030 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 5034 | 0.020 |
Why?
|
| DNA, Helminth | 1 | 2010 | 23 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2011 | 134 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2010 | 92 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2010 | 198 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2009 | 79 | 0.020 |
Why?
|
| Survival Rate | 1 | 2014 | 2112 | 0.020 |
Why?
|
| Chlamydia Infections | 1 | 2009 | 52 | 0.020 |
Why?
|
| Rats | 2 | 2005 | 3371 | 0.020 |
Why?
|
| Thermodynamics | 1 | 2009 | 145 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2020 | 17510 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2014 | 975 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2010 | 623 | 0.020 |
Why?
|
| West Indies | 1 | 2008 | 6 | 0.020 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 79 | 0.020 |
Why?
|
| Glutathione | 1 | 2010 | 201 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3355 | 0.020 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2013 | 502 | 0.020 |
Why?
|
| Multiprotein Complexes | 1 | 2009 | 196 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2009 | 809 | 0.020 |
Why?
|
| Thinness | 1 | 2008 | 71 | 0.020 |
Why?
|
| Alleles | 1 | 1993 | 1675 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 3749 | 0.020 |
Why?
|
| Income | 1 | 2008 | 137 | 0.020 |
Why?
|
| Cyclin D3 | 1 | 2007 | 11 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 4035 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 1995 | 1948 | 0.020 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2007 | 18 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2007 | 95 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2008 | 218 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2007 | 66 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2007 | 223 | 0.020 |
Why?
|
| Cell Division | 2 | 1999 | 718 | 0.010 |
Why?
|
| Quillaja Saponins | 1 | 2005 | 2 | 0.010 |
Why?
|
| Saponins | 1 | 2005 | 20 | 0.010 |
Why?
|
| Mesocricetus | 1 | 2005 | 65 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 5153 | 0.010 |
Why?
|
| Leupeptins | 1 | 2005 | 21 | 0.010 |
Why?
|
| Weight Loss | 1 | 2009 | 533 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2005 | 119 | 0.010 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 190 | 0.010 |
Why?
|
| Proteasome Inhibitors | 1 | 2005 | 53 | 0.010 |
Why?
|
| vif Gene Products, Human Immunodeficiency Virus | 1 | 2004 | 2 | 0.010 |
Why?
|
| Human Immunodeficiency Virus Proteins | 1 | 2004 | 3 | 0.010 |
Why?
|
| Gene Products, rev | 1 | 2004 | 11 | 0.010 |
Why?
|
| Necator | 1 | 2004 | 2 | 0.010 |
Why?
|
| Larva Migrans | 1 | 2004 | 6 | 0.010 |
Why?
|
| Gene Products, vif | 1 | 2004 | 7 | 0.010 |
Why?
|
| Leukemia, T-Cell | 1 | 2004 | 13 | 0.010 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2004 | 15 | 0.010 |
Why?
|
| vpr Gene Products, Human Immunodeficiency Virus | 1 | 2004 | 13 | 0.010 |
Why?
|
| rev Gene Products, Human Immunodeficiency Virus | 1 | 2004 | 15 | 0.010 |
Why?
|
| Gene Products, nef | 1 | 2004 | 18 | 0.010 |
Why?
|
| Gene Products, tat | 1 | 2004 | 27 | 0.010 |
Why?
|
| Gene Products, vpr | 1 | 2004 | 16 | 0.010 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 2004 | 32 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 191 | 0.010 |
Why?
|
| Sex Ratio | 1 | 2004 | 12 | 0.010 |
Why?
|
| Cell Transformation, Viral | 1 | 2004 | 96 | 0.010 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2004 | 61 | 0.010 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2004 | 121 | 0.010 |
Why?
|
| HTLV-I Infections | 1 | 2003 | 6 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 2003 | 33 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2005 | 759 | 0.010 |
Why?
|
| Mitosis | 1 | 2004 | 192 | 0.010 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2003 | 34 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2003 | 65 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2005 | 348 | 0.010 |
Why?
|
| Travel | 1 | 2004 | 126 | 0.010 |
Why?
|
| Mutation | 1 | 2017 | 6098 | 0.010 |
Why?
|
| Benzimidazoles | 1 | 2004 | 155 | 0.010 |
Why?
|
| Gastrointestinal Tract | 1 | 2005 | 210 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2004 | 339 | 0.010 |
Why?
|
| Schools | 1 | 2004 | 236 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2005 | 488 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2004 | 565 | 0.010 |
Why?
|
| DNA | 1 | 2007 | 1400 | 0.010 |
Why?
|
| DNA Repair | 1 | 2004 | 570 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2003 | 687 | 0.010 |
Why?
|
| Heart Failure | 1 | 2013 | 2323 | 0.010 |
Why?
|
| Fibronectins | 1 | 1999 | 99 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 2011 | 0.010 |
Why?
|
| Research Design | 1 | 2003 | 712 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 3717 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1999 | 413 | 0.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1999 | 147 | 0.010 |
Why?
|
| Transfection | 1 | 1999 | 960 | 0.010 |
Why?
|
| Quail | 1 | 1995 | 5 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 1995 | 310 | 0.010 |
Why?
|
| Exons | 1 | 1995 | 760 | 0.010 |
Why?
|